# US 2012/0232169 A1 · Highly monodisperse branched peg-lipid conjugates

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0232169 A1
- Document ID: US20120232169A1
- Status: Published application
- Kind: A1
- Application number: 13/412,676
- Filed: 2012-03-06
- Published: 2012-09-13
- Earliest claimed: 2011-03-07
- Assignees: Biozone Pharmaceuticals, Inc.
- Inventors: Nian Wu; Brian Charles Keller
- Web page: https://patentgrep.com/patent/US20120232169A1

## CPC

- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0095: {Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches (A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006)}
- A61K 9/4858: {Organic compounds}
- A61K 31/7052: having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K 38/13: Cyclosporins
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6911: {the form being a liposome}
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

(PEG)-lipid conjugates and methods of preparation are disclosed herein. Methods of preparation may involve stepwise addition of small PEG oligomers to a glycerol backbone until a desired chain size is attained. Polymers resulting from the syntheses may be highly monodisperse. The resulting polymers may comprise branched polyethyleneglycol (PEG)-lipid conjugates. The present disclosure may provide several advantages such as simplified synthesis, high product yield and low cost for starting materials. The present synthesis method may be suitable for preparing a wide range of conjugates such as PEG lipid conjugates having a glycerol-like central backbone covalently attached to two or more monodisperse PEG chains and a lipid comprising a range of diesters made from fatty acids or bile acids.

## Claims

### Claim 1

A branched polymer-lipid conjugate comprising:
a backbone;
a lipid group covalently attached to the backbone;
a branched polymer having a subchain, said branched polymer being covalently attached to said backbone; and
said polymer subchain having a MW between about 200 and 1200 daltons.

### Claim 2 (depends on 1)

The branched polymer-lipid conjugate of claim 1 wherein said polymer subchain is PEG.

### Claim 3 (depends on 1)

A chemical composition comprising a plurality of the branched polymer-lipid conjugates of claim 1 with at least about 25 percent oligomer purity.

### Claim 4 (depends on 3)

The chemical composition of claim 3 with at least about 50 percent oligomer purity.

### Claim 5 (depends on 1)

The branched polymer-lipid conjugate of claim 1 wherein said polymer subchain has a MW greater than about 350 daltons.

### Claim 6 (depends on 1)

The branched polymer-lipid conjugate of claim 1 wherein said lipid group is one of a)-f):
a) an alkyl group;
b) a dialkylglycerol ester;
c) selected from the group consisting of Butanoic acid, Hexanoic acid, Octanoic acid, Decanoic acid, Dodecanoic acid, Tetradecanoic acid, Hexadecanoic acid, Octadecanoic acid, Eicosanoic acid, Docosanoic acid, Myristoleic acid, Palmitoleic acid, Oleic acid, Linoleic acid, α-Linolenic acid, Arachidonic acid, and Erucic acid;
d) a bile acid;
e) selected from the group consisting of Cholic acid, Desoxycholic acid, 5-Cholenic acid-3β-ol, Dehydrocholic acid, Glycocholic acid, Glycodeoxycholic acid, Chenodeoxycholic acid, Glycochenodeoxycholic acid, Ursodeoxycholic acid, Lithocholic acid, Hyodeoxycholic acid, and 5β-Cholanic acid-3,7-dione; and
f) cholesterol.

### Claim 7 (depends on 1)

The branched polymer-lipid conjugate of claim 1 further comprising a second lipid group covalently attached to said backbone.

### Claim 8 (depends on 1)

The branched polymer-lipid conjugate of claim 1 further comprising a linker between said backbone and said polymer.

### Claim 9 (depends on 8)

The branched polymer-lipid conjugate of claim 8 wherein said linker is one of a) and b)
a) selected from the group consisting of —S—, —O—, —N—, —OCOO—, carbamoyl-carboxylic acid, n-amino-alkyl-amide, n-hydroxyl-alkyl-amide, alkyl diamide, diamino-carboxylic acid, n-aminoalcohol, diamine, n-amino-alkyl-carbamic acid, n-amino(methyl-thio)n-propanamide, n-mercaptocarboxylic acid, n-mercapto-alpha-aminocarboxylic acid, n-mercapto-alkyl-carbamic acid, Alkyl group, n-mercaptopropylthio)carboxylic acid, Amino-thiol, n-mercapto-alcohol, dithiol, n-amino-(methyl-thio)n-propanoic acid, n-hydroxy-carboxylic acid, n-amino-carboxylic acid, di-carboxylic acid, succinyl, diols, n-hydroxy-alkyl-carbamic acid, and n-hydroxyl-(methyl-thio)n-propanoic acid; and
b) selected from a group consisting of —O—C(O)—, —O—, —S—, and —NH—C(O)—.

### Claim 10 (depends on 1)

The branched polymer-lipid conjugate of claim 1 wherein said backbone is one of a)-d):
a) glycerol;
b) selected from the group consisting of 3-amino-1,2-propanediol, 3-bromo-1,2-propanediol, 3-chloro-1,2-propanediol, 3-fluoro-1,2-propanediol, DL-glyceric acid, diaminopropionic acid, tartaric acid, glucoheptonic acid, and 1,2,4-butanetriol, 2,2-Bis(hydroxymethyl)-butyric acid;
c) selected from the group consisting of diethylenetriamine (spermidine), triethylenetriamine (spermine), norspermidine, bis(3-aminopropyl)-1,3-propanediamine, and bis(hexamethylene)triamine; and
d) selected from the group consisting of Lysine, Aspartic Acid, Glutamic Acid, Asparagine, Glutamine, Ornithine, Serine and Threonine.

### Claim 11 (depends on 1)

The branched polymer-lipid conjugate of claim 1 comprising two or more said polymers covalently attached to said backbone.

### Claim 12 (depends on 1)

The branched polymer-lipid conjugate of claim 1 wherein said polymer subchain is selected from the group consisting of PEG, polymethylene glycol, polypropylene glycol, and copolymers comprised of at least two of the monomers selected from the group consisting of methylene glycol, propylene glycol, and ethylene glycol.

### Claim 13

A branched polymer-lipid conjugate represented by the formula:
wherein X1, X2 and X3 are same or different linkers, L1 and L2 are the same or different lipids, b is a branched polymer, P is two or more subchains, and R is a terminal group on said branched polymer.

### Claim 14 (depends on 13)

The branched polymer-lipid conjugate of claim 13 wherein said lipids have a MW between about 200 and 1200 daltons.

### Claim 15 (depends on 13)

A chemical composition comprising a plurality of the branched polymer-lipid conjugates of claim 13 with at least about 25 percent oligomer purity.

### Claim 16 (depends on 13)

The branched polymer-lipid conjugate of claim 13 wherein said lipids are one of a)-f):
a) an alkyl group;
b) a dialkylglycerol ester;
c) selected from the group consisting of Butanoic acid, Hexanoic acid, Octanoic acid, Decanoic acid, Dodecanoic acid, Tetradecanoic acid, Hexadecanoic acid, Octadecanoic acid, Eicosanoic acid, Docosanoic acid, Myristoleic acid, Palmitoleic acid, Oleic acid, Linoleic acid, α-Linolenic acid, Arachidonic acid, and Erucic acid;
d) a bile acid;
e) selected from the group consisting of Cholic acid, Desoxycholic acid, 5-Cholenic acid-3β-ol, Dehydrocholic acid, Glycocholic acid, Glycodeoxycholic acid, Chenodeoxycholic acid, Glycochenodeoxycholic acid, Ursodeoxycholic acid, Lithocholic acid, Hyodeoxycholic acid, and 5β-Cholanic acid-3,7-dione; and
f) cholesterol.

### Claim 17 (depends on 13)

The branched polymer-lipid conjugate of claim 13 wherein said linkers are one of a) and b):
a) selected from the group consisting of —S—, —O—, —N—, —OCOO—, carbamoyl-carboxylic acid, n-amino-alkyl-amide, n-hydroxyl-alkyl-amide, alkyl diamide, diamino-carboxylic acid, n-aminoalcohol, diamine, n-amino-alkyl-carbamic acid, n-amino(methyl-thio)n-propanamide, n-mercaptocarboxylic acid, n-mercapto-alpha-aminocarboxylic acid, n-mercapto-alkyl-carbamic acid, Alkyl group, n-mercaptopropylthio)carboxylic acid, Amino-thiol, n-mercapto-alcohol, dithiol, n-amino-(methyl-thio)n-propanoic acid, n-hydroxy-carboxylic acid, n-amino-carboxylic acid, di-carboxylic acid, succinyl, diols, n-hydroxy-alkyl-carbamic acid, and n-hydroxyl-(methyl-thio)n-propanoic acid; and
b) selected from a group consisting of —O—C(O)—, —O—, —S—, and —NH—C(O)—.

### Claim 18 (depends on 13)

The branched polymer-lipid conjugate of claim 13 wherein said subchains are selected from the group consisting of PEG, polymethylene glycol, polypropylene glycol, and copolymers comprised of at least two of the monomers selected from the group consisting of methylene glycol, propylene glycol, and ethylene glycol.

### Claim 19 (depends on 13)

A method for increasing solubility and/or improving pharmacological profile of an active agent with the chemical composition comprising a plurality of the branched polymer-lipid conjugates of claim 13, said method comprising the steps of:
(a) formulating the active agent with the chemical composition comprising a plurality of the branched polymer-lipid conjugates of claim 13, forming a branched polymer-lipid conjugate formulation; and
(b) administering said branched polymer-lipid conjugate formulation to an animal or human.
